The future of mental health and personal development is in psychedelics.
Psychedelics for Clinical Research
Psygen’s mission is to accelerate the research and development of psychedelic drugs for medicinal and therapeutic applications.
Psygen's Social Mandate
We are committed to donating up to 10% of all profits to our charitable foundation to provide access to therapy for low income populations, fund non-profit research programs and fund environmental programs.
Danny graduated from the University of Victoria with a degree in chemistry before becoming an early employee at Aurora Cannabis. His career with Aurora provided foundational experience in enterprise management, good manufacturing practices, and the Controlled Drugs and Substances Act.
Dr. van der Heyden’s scientific focus is on cGMP manufacture of lysergamides, tryptamines and phenethylamines for use in clinical trials, and on biotechnological approaches to assembling precursors and psychedelic drug molecules.
Mark Haden is Adjunct Professor of the UBC School of Population and Public Health. He is currently involved with the British Columbia Health Officers Council drug policy committee and provides public information on drugs and drug policy.